000 02338 a2200565 4500
005 20250514221448.0
264 0 _c20051013
008 200510s 0 0 eng d
022 _a1523-6838
024 7 _a10.1053/j.ajkd.2004.11.004
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aAnsquer, Jean-Claude
245 0 0 _aFenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
_h[electronic resource]
260 _bAmerican journal of kidney diseases : the official journal of the National Kidney Foundation
_cMar 2005
300 _a485-93 p.
_bdigital
500 _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650 0 4 _aAlbuminuria
_xepidemiology
650 0 4 _aAngiotensin II Type 1 Receptor Blockers
_xtherapeutic use
650 0 4 _aAngiotensin-Converting Enzyme Inhibitors
_xtherapeutic use
650 0 4 _aAntihypertensive Agents
_xtherapeutic use
650 0 4 _aBlood Pressure
650 0 4 _aBody Mass Index
650 0 4 _aCreatinine
_xblood
650 0 4 _aDiabetes Mellitus, Type 2
_xcomplications
650 0 4 _aDiabetic Nephropathies
_xepidemiology
650 0 4 _aDisease Progression
650 0 4 _aDouble-Blind Method
650 0 4 _aFemale
650 0 4 _aFenofibrate
_xadministration & dosage
650 0 4 _aFibrinogen
_xanalysis
650 0 4 _aFollow-Up Studies
650 0 4 _aGlycated Hemoglobin
_xanalysis
650 0 4 _aHomocysteine
_xblood
650 0 4 _aHumans
650 0 4 _aHyperlipidemias
_xcomplications
650 0 4 _aHypertension
_xcomplications
650 0 4 _aHypolipidemic Agents
_xadministration & dosage
650 0 4 _aIncidence
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aModels, Biological
650 0 4 _aSmoking
_xepidemiology
650 0 4 _aTreatment Outcome
700 1 _aFoucher, Christelle
700 1 _aRattier, Stephanie
700 1 _aTaskinen, Marja-Riitta
700 1 _aSteiner, George
773 0 _tAmerican journal of kidney diseases : the official journal of the National Kidney Foundation
_gvol. 45
_gno. 3
_gp. 485-93
856 4 0 _uhttps://doi.org/10.1053/j.ajkd.2004.11.004
_zAvailable from publisher's website
999 _c15427678
_d15427678